Medidata NEXT London 2026: AI Moves from Pilot Purgatory to Platform Scale

Medidata Solutions' (Medidata) NEXT London 2026 marked the shift from AI experimentation to enterprisewide agentic deployment, anchored by the commercial launch of Medidata Plus and the full rollout of Dot. Key innovations include AI-driven simulation workspaces for protocol and enrollment planning, a proprietary Patient Burden Index, GenAI-powered site selection, and an expanded patient engagement platform that integrates continuous sensor data. Customer evidence, including a 37% enrollment uplift in atopic dermatitis trials and up to 70% reduction in budget build times, confirmed operational impact. Medidata also presented its "orchestrated intelligence" vision, extending clinical research intelligence across the life sciences value chain through partnerships with Anthropic, NVIDIA, and Mistral.Clinical organizations should prioritize data standardization, adopt simulation and site selection tools early in protocol design, and evaluate contract research organization (CRO) partners on AI readiness. Medical device companies navigating the evolving regulatory environment in 2026 should treat early platform engagement as a strategic opportunity."Medidata NEXT London 2026 showed an industry moving from AI ambition to AI accountability. The evidence is real. Enrollment gains, faster builds, smarter site selection, and platform models such as Medidata's offer one indication of how these capabilities can move from pilots to enterprise scale. For medical device companies, the moment to start engaging is now while both the underlying platforms and regulatory landscape are still being defined," says Silvia Piai, research director, IDC.